Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis-Reference-Cited by-同舟云学术

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis

Published:2022-10-18 Issue:1 Volume:34 Page:
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Elgaard Cathrine Dawn Büttner¹²^ORCID,Iversen Lars¹²^ORCID,Hjuler Kasper Fjellhaugen¹²^ORCID

Affiliation:

1. Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark

2. Danish National Center for Autoimmune Diseases, Aarhus University Hospital, Aarhus, Denmark

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2022.2133531

Reference53 articles.

1. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis

2. The IL-23/IL-17 axis in psoriatic arthritis

3. Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12

4. Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics

5. Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target;Expert Opinion on Biological Therapy;2024-09-08

2. Targeting cytokines in psoriatic arthritis;Cytokine & Growth Factor Reviews;2024-08

3. Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice;Anais Brasileiros de Dermatologia;2024-08

4. Real-Life Comparative Effectiveness of IL-23 Inhibitors in the Treatment of Moderate to Severe Psoriasis: A Multicenter Experience;Dermatology Practical & Conceptual;2024-07-31

5. Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real‐life clinical practice;Experimental Dermatology;2024-07-30